Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK Inhibitors). It is an inhibitor of the JAK1 and ...

At this time, I would like to welcome everyone to Karyopharm Therapeutics third quarter 2024 financial results conference ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...

Pharmaxis Ltd (AU:SNT) has released an update. Syntara Limited’s interim results from its Phase 2 trial for the myelofibrosis treatment ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

MaaT Pharma, a late-stage clinical biotech company, reports Third Quarter 2024 financial results and announces management changes.

Karyopharm (KPTI) stock rose after redesigning its Phase 3 trial for selinexor in myelofibrosis patients based on FDA ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...